Q2 EPS Estimate for Entrada Therapeutics Lowered by Analyst

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2025 earnings estimates for shares of Entrada Therapeutics in a report issued on Sunday, May 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($0.89) per share for the quarter, down from their previous estimate of ($0.75). The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. Roth Capital also issued estimates for Entrada Therapeutics' Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.33) EPS, Q1 2026 earnings at ($1.11) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.39) EPS and FY2026 earnings at ($5.10) EPS.

Separately, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Monday, March 31st.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock traded down $0.13 during trading on Wednesday, hitting $7.97. 47,932 shares of the company's stock were exchanged, compared to its average volume of 129,414. Entrada Therapeutics has a 52-week low of $7.10 and a 52-week high of $21.79. The business has a 50-day simple moving average of $8.94 and a 200-day simple moving average of $13.40. The stock has a market capitalization of $302.30 million, a price-to-earnings ratio of 5.01 and a beta of 0.04.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Trexquant Investment LP bought a new position in shares of Entrada Therapeutics during the 1st quarter valued at about $101,000. WCG Wealth Advisors LLC boosted its holdings in shares of Entrada Therapeutics by 20.0% during the first quarter. WCG Wealth Advisors LLC now owns 28,830 shares of the company's stock worth $261,000 after purchasing an additional 4,800 shares during the period. Merck & Co. Inc. acquired a new stake in shares of Entrada Therapeutics during the first quarter worth approximately $15,728,000. AlphaQuest LLC boosted its holdings in shares of Entrada Therapeutics by 188.2% during the first quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock worth $105,000 after purchasing an additional 7,616 shares during the period. Finally, Martingale Asset Management L P lifted its stake in Entrada Therapeutics by 4.0% in the first quarter. Martingale Asset Management L P now owns 40,163 shares of the company's stock valued at $363,000 after acquiring an additional 1,540 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.